The agency will put that question to its panel of independent advisers next Tuesday and weigh their advice before making its own decision. But agency reviewers stopped short of calling for Pfizer’s shot to be authorized. In their analysis, FDA scientists concluded that in almost every scenario the vaccine’s benefit for preventing hospitalizations and death from COVID-19 would outweigh any serious potential side effects in children. The agency will ask a panel of outside vaccine experts to vote on that question. The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11.
weighs beginning vaccinations in youngsters.
WASHINGTON (AP) – Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S.
0 kommentar(er)
